LXRX News & Events

Lexicon (LXRX) and Novo Nordisk (NVO) announced that Novo Nordisk has initiated a Phase 1 study with LX9851, an oral non-incretin development candidate. In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon has earned a second $10M milestone payment in 2026 from Novo Nordisk following initial dosing requirements in the Phase 1 study and is eligible for a third $10M milestone payment that may be achieved later this year. In total, Lexicon is eligible to receive up to $1B in upfront and potential development, regulatory and sales milestone payments. Lexicon is also entitled to tiered royalties on net sales of LX9851.

Lexicon Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes. The congress is being held March 11-14, 2026, in Barcelona, Spain. "Recognizing that a patient's kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-designed trials in patients with type 1 diabetes and were encouraged to find that treatment with sotagliflozin resulted in improvements in multiple efficacy measures after one year in both those with normal kidney function and those with mildly reduced kidney function," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer. "Not only was sotagliflozin shown to improve cardiometabolic parameters in this patient population, but it also reduced clinically important hypoglycemia events, which are a leading cause of acute mortality and morbidity and can be life-threatening." Lexicon remains on track to resubmit the New Drug Application for ZYNQUISTA glycemic control in patients with type 1 diabetes in 2026 based upon U.S. Food and Drug Administration feedback and additional clinical data received to date from the STENO1 study